HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Butel, J. S. Articles by Nachtigal, M. Search for Related Content PubMed Articles by Butel, J. S. Articles by Nachtigal, M.

Malignant Transformation in Vitro by "Non-Oncogenic" Variants of Defective SV40 (PARA)¹

Department of Virology and Epidemiology, Baylor College of Medicine, Houston, Texas 77025

Abstract

Four variants of PARA (defective SV40)-adenoviruses which appear to be "nononcogenic" in newborn hamsters were found to be able to transform Syrian hamster lung and kidney cells in vitro. All the transformed cell lines contained SV40 T antigen. With one exception, the transformed cell lines were transplantable in syngeneic weanling hamsters. However, a wide spectrum of transplantability was observed. Some of the cell lines transformed by "non-oncogenic" variants of PARA were highly transplantable and others induced only rare tumors with long latent periods. In contrast, all the cell lines established following transformation by oncogenic variants of PARA were readily transplantable in vivo. These results indicate that these "non-oncogenic" variants of PARA possess the potential for malignant transformation of cells.

Footnotes

¹ This investigation was supported in part by Research Grant CA 04600 from the National Cancer Institute, National Institutes of Health, and by a grant from the M.D. Anderson Foundation, Houston, Texas.

² Recipient of Research Career Development Award 5-K3-CA 38,614 from the National Cancer Institute, National Institutes of Health.

³ The work in this paper was undertaken during the tenure of a Research Training Fellowship awarded by the International Agency for Research on Cancer, While on leave from the Nicolau Institute for Virology, Bucharest.